Efficacy/safety Of Ocrelizumab In Relapsing-remitting MS Patients With Suboptimal Response To Prior Disease-modifying Therapies (1-yr Interim Results)

被引：0
作者：
Vermersch, P. [1 ]
Eralinna, J. [2 ]
Nicholas, R. [3 ,4 ]
Oreja-Guevara, C. [5 ]
Siva, A. [6 ]
Van Wijmeersch, B. [7 ,8 ]
Wiendl, H. [9 ]
Buffels, R. [10 ]
Wei, W. [10 ]
Comi, G. [11 ]
机构：
[1] Univ Lille, Lille, France
[2] NEO Res, Turku, Finland
[3] Imperial Coll Healthcare NHS Trust, London, England
[4] Imperial Coll, London, England
[5] Hosp Clin San Carlos, Madrid, Spain
[6] Istanbul Univ, Cerrahpasa Fac Med, Cerrahpasa, Turkey
[7] Univ Hasselt, Overpelt, Belgium
[8] Rehabil & MS Ctr, Overpelt, Belgium
[9] Univ Munster, Munster, Germany
[10] F Hoffmann Roche Ltd, Basel, Switzerland
[11] Univ Vita Salute San Raffaele, Milan, Italy
来源：
MULTIPLE SCLEROSIS JOURNAL | 2020年 / 26卷 / 1_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P035
引用
收藏
页码：32 / 32
页数：1
相关论文
共 50 条
  • [31] Comparative safety of high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis
    Sladowska, Katarzyna
    Kawalec, Pawel
    Holko, Przemyslaw
    Osiecka, Oktawia
    NEUROLOGICAL SCIENCES, 2022, 43 (09) : 5479 - 5500
  • [32] Alemtuzumab Safety, Efficacy, and Tolerability in Paediatric Patients with Active Relapsing-Remitting Multiple Sclerosis Despite Prior Treatment with Disease-Modifying Therapy: LemKids Study Design
    Chitnis, T.
    Banwell, B.
    Arnold, D.
    Arque, M. -J.
    Chirieac, M.
    Rakhade, S.
    Jacobs, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 130 - 130
  • [33] Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis
    Li, Huihui
    Hu, Fengli
    Zhang, Yanli
    Li, Kai
    JOURNAL OF NEUROLOGY, 2020, 267 (12) : 3489 - 3498
  • [34] Assessing the cumulative effects of disease-modifying therapies on the current risk of irreversible disability in patients with relapsing-remitting multiple sclerosis
    Rollot, F.
    Casey, R.
    Debouverie, M.
    Edan, G.
    Wiertlewski, S.
    Leray, E.
    Vukusic, S.
    Laplaud, D-A
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 344 - 345
  • [35] COMPARING THE EFFICACY OF FIRST AND SECOND GENERATION DISEASE-MODIFYING THERAPIES FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS: A NETWORK META-ANALYSIS
    Fogarty, E.
    Schmitz, S.
    Walsh, C.
    Barry, M.
    VALUE IN HEALTH, 2013, 16 (07) : A618 - A618
  • [36] High-Efficacy Disease-Modifying Therapies in People with Relapsing-Remitting Multiple Sclerosis: The Role of Risk Attitude in Treatment Decisions
    Maurino, Jorge
    Sotoca, Javier
    Sempere, Angel P.
    Brieva, Luis
    Lopez de Silanes, Carlos
    Caminero, Ana B.
    Terzaghi, Maria
    Gracia-Gil, Julia
    Saposnik, Gustavo
    PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2021, 14 (02) : 241 - 248
  • [37] Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: interim safety and efficacy results from the Phase 3 EVOLVE-MS-1 Study
    Singer, B. A.
    Drulovic, J.
    Chen, H.
    Lyons, J.
    Then Bergh, F.
    Negroski, D.
    Kapadia, S.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 619 - 620
  • [38] Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: interim safety and efficacy results from the phase 3 evolve-ms-1 study
    Wray, S.
    Singer, B.
    Drulovic, J.
    Chen, H.
    Hanna, J.
    Lyons, J.
    Bergh, F. Then
    Negroski, D.
    Kapadia, S.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 214 - 215
  • [39] Cladribine Tablets in Patients With Relapsing-Remitting Multiple Sclerosis or Active Secondary Progressive Multiple Sclerosis After Suboptimal Response to a Disease-Modifying Therapy (CLICK-MS and MASTER-2): Interim Baseline and Safety Review (P1-1.Virtual)
    Miravalle, Augusto A.
    Katz, Joshua
    Robertson, Derrick
    Aldridge, Julie
    Evans, Emily
    Harlow, Danielle E.
    Lebson, Lori A.
    Sloane, Jacob A.
    Bass, Ann D.
    Fox, Edward J.
    NEUROLOGY, 2022, 98 (18)
  • [40] Cost and effectiveness of autologous haematopoietic stem cell transplantation and high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis
    Mariottini, Alice
    Nozzoli, Chiara
    Carli, Ilaria
    Landi, Filippo
    Gigli, Valentina
    Repice, Anna Maria
    Ipponi, Alessandra
    Cecchi, Michele
    Boncompagni, Riccardo
    Saccardi, Riccardo
    Massacesi, Luca
    NEUROLOGICAL SCIENCES, 2024, 45 (07) : 3379 - 3387
12345